Patents Represented by Attorney Robert E. Carnahan
  • Patent number: 4504657
    Abstract: A novel crystalline monohydrate of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-methyl-3-cephem-4 -carboxylic acid is prepared and found to be a stable useful form of the cephalosporin antibiotic especially advantageous for pharmaceutical formulations.
    Type: Grant
    Filed: March 16, 1982
    Date of Patent: March 12, 1985
    Assignee: Bristol-Myers Company
    Inventors: Daniel Bouzard, Abraham Weber, Jacques Stemer
  • Patent number: 4487769
    Abstract: Mitomycin A, mitomycin C, and porfiromycin react with amide acetals and other amide derivatives to produce amidine derivatives having antitumor activity against experimental animal tumors. The amidines derived from mitomycin C are useful intermediates in reactions with primary amines to produce both known and novel 7-amino-9a-methoxymitosanes having antitumor activity against experimental animal tumors.
    Type: Grant
    Filed: May 9, 1983
    Date of Patent: December 11, 1984
    Assignee: Bristol-Myers Company
    Inventors: Dolatrai M. Vyas, Takushi Kaneko, Terrence W. Doyle
  • Patent number: 4465683
    Abstract: 2-[4-[4-Arylpiperazin-1-yl]butyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-ones are anti-psychotic agents.
    Type: Grant
    Filed: September 14, 1979
    Date of Patent: August 14, 1984
    Assignee: Mead Johnson & Company
    Inventor: Duane F. Morrow
  • Patent number: 4451456
    Abstract: An antitumor antibacterial complex referred to as BBM-928 is described which is produced by microbiological fermentation under controlled conditions using a species of actinomycetes. The bioactive components of the complex have pronounced antitumor activity and are moderately to weakly active against gram-positive and acid fast bacteria but practically inactive against gram-negative bacteria and fungi. Based on median survival time, the component designated BBM-928A is substantially more active than mitomycin C by a factor of 10 to 300 fold against intraperitoneally implanted mouse tumors.
    Type: Grant
    Filed: June 21, 1982
    Date of Patent: May 29, 1984
    Assignee: Bristol-Myers Company
    Inventors: Hideo Koshiyama, Fumihide Sakai, Hiroaki Ohkuma
  • Patent number: 4448958
    Abstract: Crude cephalosporin 7-[.alpha.-(2-aminomethylphenyl)acetamido]-3-[(1-carboxymethyltetrazol-5-y lthio)methyl]-3-cephem-4-carboxylic acid is purified by converting it to its salt with benzyldimethylamine, recovering said salt and from it regenerating said cephalosporin in purified form.
    Type: Grant
    Filed: October 20, 1982
    Date of Patent: May 15, 1984
    Assignee: Bristol-Myers Company
    Inventors: Paul D. Sleezer, Richard R. Smith
  • Patent number: 4444687
    Abstract: 2.beta.-Chloromethyl-2.alpha.-methylpenam-3.alpha.-carboxylic acid sulfone and salts and esters thereof were synthesized and found to be potent inhibitors of .beta.-lactamases.
    Type: Grant
    Filed: April 12, 1983
    Date of Patent: April 24, 1984
    Assignee: Bristol-Myers Company
    Inventor: William J. Gottstein
  • Patent number: 4430346
    Abstract: The novel compound represented by the general formula (I) ##STR1## (wherein R represents a hydrogen atom, an alkanoyl group of 1 to 14 carbon atoms, or an arylcarbonyl group), and an acid addition salt thereof [on condition that when R is a hydrogen atom, the hydrochloride exhibits an optical rotation of [.alpha.].sub.D.sup.22 -1.degree. .+-.2.degree. (c, 2 water)] has antitumor activity in experimental animals.
    Type: Grant
    Filed: May 7, 1982
    Date of Patent: February 7, 1984
    Assignee: Bristol-Myers Company
    Inventors: Hamao Umezawa, Tomio Takeuchi, Shinichi Kondo, Hironobu Iinuma, Daishiro Ikeda, Teruya Nakamura, Akio Fujii
  • Patent number: 4416874
    Abstract: BBM-928A solutions suitable for parenteral use in animal experiments and having concentrations in the range of 1 mg/ml to 5 mg/ml are described.
    Type: Grant
    Filed: March 5, 1982
    Date of Patent: November 22, 1983
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Edward C. Shinal
  • Patent number: 4406887
    Abstract: Bacteroides which are uniformly resistant to ceftazidime fail to grow when exposed to 2.beta.-chloromethyl-2.alpha.-methylpenam-3.alpha.-carboxylic acid (BL-P 2013), which itself is non-inhibitory, in combination with ceftazidime. Bacteroides infections are abated by treatment of the infected mammal with this combination of substances.
    Type: Grant
    Filed: October 13, 1981
    Date of Patent: September 27, 1983
    Assignee: Bristol-Myers Company
    Inventors: Maxwell Gordon, I. Jacob Pachter
  • Patent number: 4404380
    Abstract: Imidazopyrimidinones and other diazaheterocyclopyrimidinones having an additional fused imidazole or triazole ring have utility as bronchodilators, mediator release inhibitors, phosphodiesterase inhibitors, and peripheral vasodilators. They are orally active and useful in the prophylaxis and treatment of asthma. A preferred compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]-purin-9(4H)-one.
    Type: Grant
    Filed: August 14, 1980
    Date of Patent: September 13, 1983
    Assignee: Mead Johnson & Company
    Inventor: Davis L. Temple, Jr.
  • Patent number: 4372887
    Abstract: N-Phenyl amidines which have diuretic, antithrombogenic, smooth muscle relaxant, anti-inflammatory and antiarrhythmic properties have been discovered. They are prepared by reacting a substituted aniline with a carboxamide selected from the group consisting of amides and lactams in the presence of phosphorus oxychloride. Typical examples of substituted N-phenyl amidines thus obtained are 5-methyl-2-(N-phenylbenzylamino)-1-pyrroline, 2-(N-phenylbenzylamino)-1-pyrroline, 3-[(N-1-pyrrolin-1-yl-p-anisidino)methyl]indole and 4,5,6,7,8,9-hexahydro-2-(N-phenylphenethylamino)-3H-azonine. Indole substituted N-phenyl amidines can be rearranged to provide iminopyrrolinidinylindoles which are useful as diuretic, antithrombogenic and smooth muscle relaxant agents. In the case of 3-[(N-1-pyrrolin-2-yl-p-anisidino)methyl]indole, the rearranged product is 3-[[2-p-methoxyphenylimino)-1-pyrrolidinyl]methyl]indole.
    Type: Grant
    Filed: November 24, 1980
    Date of Patent: February 8, 1983
    Assignee: Mead Johnson & Company
    Inventors: Yao H. Wu, Walter G. Lobeck, Jr.
  • Patent number: 4370321
    Abstract: Oral treatment with megestrol acetate improves survival rate and reduces the recurrence rate in the adjuvant therapy of breast cancer following mastectomy.
    Type: Grant
    Filed: September 1, 1976
    Date of Patent: January 25, 1983
    Assignee: Mead Johnson and Company
    Inventors: Martin O. Greaney, Merritt R. Callantine
  • Patent number: 4367335
    Abstract: Piperazinyl derivatives containing a 3-alkylene-2,4-thiazolidinedione heterocyclic component with relatively selective psychotropic properties are disclosed. The compound 3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,4-thiazolidinedione which has selective anxiolytic activity constitutes a typical embodiment of the invention.
    Type: Grant
    Filed: August 3, 1981
    Date of Patent: January 4, 1983
    Assignee: Mead Johnson & Company
    Inventors: Davis L. Temple, Jr., Richard E. Yeager
  • Patent number: 4366156
    Abstract: Imidazopyrimidinones and other diazaheterocyclopyrimidinones having an additional fused imidazole or triazole ring have utility as bronchodilators, mediator release inhibitors, phosphodiesterase inhibitors, and peripheral vasodilators. They are orally active and useful in the prophylaxis and treatment of asthma. A preferred compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one.
    Type: Grant
    Filed: November 24, 1980
    Date of Patent: December 28, 1982
    Assignee: Mead Johnson & Company
    Inventor: Davis L. Temple, Jr.
  • Patent number: 4360458
    Abstract: An antitumor antibacterial complex referred to as BBM-928 is described which is produced by microbiological fermentation under controlled conditions using a species of actinomycetes. The bioactive components of the complex have pronounced antitumor activity and are moderately to weakly active against gram-positive and acid fast bacteria but practically inactive against gram-negative bacteria and fungi. Based on median survival time, the component designated BBM-928A is substantially more active than mitomycin C by a factor of 10 to 300 fold against intraperitoneally implanted mouse tumors.
    Type: Grant
    Filed: March 6, 1980
    Date of Patent: November 23, 1982
    Assignee: Bristol-Myers Company
    Inventors: Hideo Koshiyama, Fumihide Sakai, Hiroaki Ohkuma
  • Patent number: 4357465
    Abstract: New routes are provided for the synthesis of 3',4'-dideoxykanamycin B which is effective in inhibiting kanamycin-resistant organisms from kanamycin B through new intermediate, of which a fundamental process comprises a new reaction of a 3',4'-epoxy derivative of amino- and hydroxyl-protected kanamycin B with a xanthate to form a corresponding 3',4'-dideoxy-3'-eno derivative followed by removal of the amino- and hydroxyl-protecting groups thereof and by hydrogenation of the resulting 3',4'-dideoxy-3'-eno-kanamycin B. A 3',4'-episulfide derivative corresponding to the 3',4'-epoxy derivative which is formed as second product in the reaction of 3',4'-epoxy derivative with xanthate is also used as intermediate for the preparation of 3',4'-dideoxykanamycin B.
    Type: Grant
    Filed: September 15, 1980
    Date of Patent: November 2, 1982
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Hamao Umezawa, Sumio Umezawa, Shigeo Seki, Shunzo Fukatsu, Shuntaro Yasuda
  • Patent number: 4351766
    Abstract: Trimethylsilyl or another easily hydrolyzed ester of 6-trimethylsilyloxycarbonylaminopenicillanic acid was prepared by bubbling dry carbon dioxide into an anhydrous solution of the corresponding 6-trimethylsilylaminopenicillanate and found to be a useful intermediate in the production of penicillins, e.g., amoxicillin and ampicillin, by its acylation in anhydrous media with the appropriate acid chloride or acid chloride hydrochloride.
    Type: Grant
    Filed: August 13, 1981
    Date of Patent: September 28, 1982
    Assignee: Bristol-Myers Company
    Inventors: Derek Walker, Herbert H. Silvestri, Chester Sapino, David A. Johnson
  • Patent number: 4351939
    Abstract: Novel spiro-quaternary ammonium halides are disclosed. The new compounds are particularly valuable as intermediates in preparation of N-(2-pyrimidinyl)piperazinylalkyl derivatives of azaspiroalkanediones such as the psychopharmacologic agent 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dio ne.
    Type: Grant
    Filed: October 16, 1980
    Date of Patent: September 28, 1982
    Assignee: Mead Johnson & Company
    Inventors: Jack C. Simms, deceased, Old National Bank in Evansville, administrator
  • Patent number: 4343940
    Abstract: 4-Ethyl-6-methoxy-7-(oxiranylmethoxy)quinazoline and its isomer 4-ethyl-7-methoxy-6-(oxiranylmethoxy)quinazoline have potent anti-tumor activity in animals.
    Type: Grant
    Filed: March 6, 1981
    Date of Patent: August 10, 1982
    Assignee: Mead Johnson & Company
    Inventors: William E. Kreighbaum, William T. Comer
  • Patent number: RE31730
    Abstract: A novel crystalline monohydrate of 7-[D-.alpha.-amino-.alpha.-(p-hydroxyphenyl)acetamido]-3-methyl-3-caphem-4 -carboxylic acid is prepared and found to be astable useful form of the cephalosporin antibiotic especially advantageous for pharmaceutical formulations.
    Type: Grant
    Filed: November 30, 1982
    Date of Patent: November 13, 1984
    Assignee: Bristol-Myers Company
    Inventors: Daniel Bouzard, Abraham Weber, Jacques Stemer